QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel
News Feb 15, 2010
QIAGEN N.V. and Celera Corporation have announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay.
The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run. Financial details were not disclosed.
Under the terms of the agreement, QIAGEN has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The new ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.
“Celera’s significant experience in the development and manufacturing of molecular diagnostic products is a very valuable resource and this relationship can accelerate our effort to further expand our molecular diagnostic solution portfolio,” said Peer Schatz, CEO of QIAGEN. “We believe that this new product has the potential to provide significant value for laboratories, healthcare professionals and patients worldwide.”
“We are pleased to have entered into this agreement with QIAGEN as we look toward the development and marketing of a molecular diagnostic solution to address certain infectious respiratory diseases and provide our customers with a product of the highest quality,” said Kathy Ordonez, CEO of Celera.
The new ResPlex kits will be available through QIAGEN’s existing sales channels. The new test will be submitted for regulatory approval in the United States and Europe.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE